- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Ajanta Pharma has announced a board meeting where it approved the audited consolidated financial results for the quarter and year ended 31 March 2025. Revenue from operations increased by 10% to ₹4,648 crore, with profit after tax rising 13% to ₹920 crore. The company declared a total payout of ₹700 crore for the financial year, equivalent to 76% of PAT. Ajanta is actively expanding its branded generics portfolio, particularly in India and Africa, and demonstrates strong operational cash flow, reflecting a solid performance with positive growth metrics.